A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms

A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms

Myeloproliferative neoplasms are a varied group of disorders that can have prolonged chronic phases, but eventually accelerate and can transform into a secondary acute myeloid leukemia that is ultimately fatal. Triapine is a novel inhibitor of the M2 subunit of ribonucleotide reductase. Sequential i...

Full description

Bibliographic Details
Main Authors: Joshua F. Zeidner, Judith E. Karp, Amanda L. Blackford, B. Douglas Smith, Ivana Gojo, Steven D. Gore, Mark J. Levis, Hetty E. Carraway, Jacqueline M. Greer, S. Percy Ivy, Keith W. Pratz, Michael A. McDevitt
Format: Article
Language:English
Published: Ferrata Storti Foundation 2014-04-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/6997

Internet

https://haematologica.org/article/view/6997

Similar Items